Activity Overview
Welcome to this OncoByte Personalized Learning Pathway!
Each OncoByte video consists of a 5-minute presentation delivered by our expert faculty on practice-ready updates in triple-negative breast cancer (TNBC) or a 10-minute panel discussion where our expert faculty will help you synthesize the latest information and data about TROP2-targeted ADCs to help guide your incorporation of these novel treatments into everyday practice.
For each module, select at least 3 videos to build a custom microlearning program focused only on your interests.
Target Audience
This educational program is primarily directed toward medical oncologists, surgical oncologists, advanced practice providers, nurses, and pharmacists involved in the management of patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe unmet needs for treating metastatic TNBC and the rationale for targeting TROP2
- Evaluate recent data from clinical trials assessing the role of ADCs in the frontline treatment of metastatic TNBC
- Implement novel frontline treatment options for patients with metastatic TNBC across biomarker subgroups, including PD-L1–positive, PD-L1–negative, and IO-ineligible
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine, Geffen School of Medicine
University of California, Los Angeles
Program Director, Breast Medical Oncology
Assistant Chief of Translational Research, Division of
Hematology-Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome; Grant/Research Funding: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, OnKure, Pfizer
Alexis LeVee, MD
Clinical Instructor of Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Incyclix Bio
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This
accredited continuing education activity was planned in accordance with the
ACCME Standards for Integrity and Independence to ensure balance, objectivity,
independence, and scientific rigor. Faculty were instructed to use generic
names when possible and to base recommendations on the best available evidence.
Proprietary product names may be referenced in clinical discussion for
educational purposes only and do not imply endorsement.
This activity
may include discussion of investigational, unapproved, or off‑label uses of drugs or devices.
Learners are advised to consult prescribing information for products discussed.
Content is provided for educational purposes only and is not a substitute for
the independent clinical judgment of a health care professional. Learners are
encouraged to critically evaluate the information presented and apply their own
clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
